SEC Form 4 · accession 0001209191-17-050305
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Russell Skibsted
Officer — Chief Financial Officer
Period of report
Aug 23, 2017
Accepted (ET)
Aug 25, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Aug 23, 2017 | P | 2,000 | $2.6424 | A | 2,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchase price per share represents a weighted average of prices ranging from $2.6373 to $2.6475 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2Does not include shares that may be acquired upon the exercise of certain stock options.